

*Copy of Filed Response*  
RJS

**RECEIVED**  
**CENTRAL FAX CENTER**  
**JUN 01 2011**

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: Watkins, Jeffry D. Group Art Unit: 1644

Serial No.: 10/553,938 Examiner: Ron Schwadron, Ph.D.

Application Date: October 21, 2005 Confirmation No.: 8652

For: CD20 Binding Molecules

Docket No.: X-16760A

**AMENDMENT AND RESPONSE TO FINAL REJECTION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the Final Office Action dated April 1, 2011 (hereinafter, the "Final Office Action") in regards to the patent application captioned above. This amendment and response is being filed within two months of the mailing date of the Final Office Action in order to provoke an Advisory Action from the Examiner if he concludes that this reply does not place the application in condition for allowance.

A Declaration under 37 C.F.R. § 1.132 is concurrently submitted herewith.

A Terminal Disclaimer on form PTO/SB26 in compliance with 37 CFR § 1.321(c) in response to the Examiner's nonstatutory double patenting rejection is also submitted herewith.

Amendments to the specification are found on page 2 of this paper.

Amendments to the claims are reflected in the listing of the claims beginning on page 3 of this paper.

Remarks begin on page 5 of this paper.